Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Durata Therapeutics, Inc. (DRTX)
|
Add to portfolio |
|
|
|
| Price: |
$24.16
| | Metrics |
| OS: |
26.7
|
M
| |
|
|
| Market cap: |
$645
|
M
| |
1811
|
% ROIC
|
|
Net debt:
|
$29.5
|
M
| |
0.4
|
x Debt/EBITDA
|
|
EV:
|
$674
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$73.8
|
M
| |
9.1
|
x EV/EBITDA
|
|
EBIT
|
$72.9
|
M
| |
9.3
|
x EV/EBIT
|
| EPS |
($2.82)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-13 | Nov-04-13 | Dec-31-12 | Nov-04-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 2.2 | 340.3 | 0.0 | 226.3 | 71.1 | 27.8 |
| Revenue growth | | 50.3% | -100.0% | | 155.9% | |
| Cost of goods sold | -115.6 | 0.0 | -125.1 | 0.0 | 0.0 | 0.0 |
| Gross profit | 117.8 | 340.3 | 125.1 | 226.3 | 71.1 | 27.8 |
| Gross margin | 5293.6% | 100.0% | | 100.0% | 100.0% | 100.0% |
| Research and development | 37.3 | 124.2 | 51.7 | 86.8 | 30.1 | 4.8 |
| General and administrative | 18.6 | 36.4 | 9.8 | 17.8 | 4.3 | 2.8 |
| EBIT | 58.0 | 179.7 | 63.7 | 121.7 | 36.7 | 20.2 |
| EBIT margin | 2606.7% | 52.8% | | 53.8% | 51.6% | 72.7% |
| Pre-tax income | 60.9 | 174.0 | 62.5 | 113.1 | 35.5 | 13.9 |
| Income taxes | 1.3 | -4.5 | 0.0 | -5.8 | -2.5 | -2.9 |
| Tax rate | 2.1% | | 0.0% | | | |
| Net income | -62.1 | -169.4 | -62.5 | -107.3 | -33.0 | -11.0 |
| Net margin | -2791.6% | -49.8% | | -47.4% | -46.4% | -39.6% |
| |
| Diluted EPS | ($2.57) | | ($7.48) | | ($551.51) | ($469.91) |
| Shares outstanding (diluted) | 24.2 | | 8.4 | | 0.1 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|